Neuren jumps 11pc on US patent win
Mid-cap pharma stock Neuren has jumped almost 11 per cent after announcing that the United States Patent and Trademark Office has allowed its patent application for a treatment of Pitt Hopkins syndrome (PTHS).
There are currently no approved treatments for PTHS, which has a severely debilitating impact on the lives of patients, the company said in a statement to the ASX on Thursday before the market opened.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.11 |
Change
-0.090(0.63%) |
Mkt cap ! $1.750B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.01 | $6.213M | 438.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7700 | $14.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.16 | 3278 | 1 |
View Market Depth
| Last trade - 16.16pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |